Reproducible dry Age-Related Macular Degeneration Models.

Age-Related Macular Degeneration (AMD) has a global prevalence of around 170 million. Dry AMD separates itself from wet AMD by lacking any vascular involvement in its pathological course. 85 to 90% of AMD cases are dry; they cannot be treated, and might develop into wet AMD which is the more severe, but treatable, form.

Data from the WHO shows that AMD has been holding a spot in the world’s top 7 causes of blindness and visual impairment for years now. This has to change. With your critical pipelines and our models at PharmaLegacy, AMD might one day lose its spot on the world’s leading causes of visual impairment and blindness.

Contact Us


Pioneering Healthcare Solutions:

  • Operations and IT structured for maximum protection of clients’ data and IP
  • Scientific staff with an average of over 15 years of experience in pharmacology
  • AAALAC accredited vivarium
  • Capacity to run 200+ concurrent animal studies

Looking for data-driven insights for your macular degeneration studies? Talk to PharmaLegacy

Contact Us

Top Pharmaceutical Companies Trust PharmaLegacy For Their Preclinical Ophthalmology Studies

Your preclinical ophthalmology studies call for flawless and affordable ophthalmology models. Download our Ophthalmology brochure and see how our models and decades of expertise can give you the clarity you need in your pipeline.


    We’re ready when you are.

    Tell us your pharmacology challenges.